Reserpine in the Treatment of Neuropsychiatric Disorders

Clough, Paul W.

doi:10.7326/0003-4819-43-3-632

Cited by 4 publications

(2 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The first antipsychotic, chlorpromazine, which was originally developed as an antihistaminergic drug for use in a range of conditions, including nausea and allergies, and reserpine, a Rauvolfia alkaloid, were demonstrated to be effective in treating the psychosis of schizophrenia in the early 1950s. Shortly afterward, more potent phenothiazines and butyrophenones drugs were developed and proved to be highly efficacious in alleviating symptoms of schizophrenia .…”

Section: The History Of Pathological Hypotheses In Schizophreniamentioning

confidence: 99%

Glutamate hypothesis in schizophrenia

Uno

Coyle

2019

Psychiatry Clin Neurosci

282

172

View full text Add to dashboard Cite

Schizophrenia is a chronic and severe psychiatric disorder that has profound impact on an individual’s life and on society. Thus, developing more effective therapeutic interventions is essential. Over the past quarter‐century, an abundance of evidence from pharmacologic challenges, post‐mortem studies, brain imaging, and genetic studies supports the role of glutamatergic dysregulation in the pathophysiology of schizophrenia, and the results of recent randomized clinical trials based on this evidence have yielded promising results. In this article, we review the evidence that alterations in glutamatergic neurotransmission, especially focusing on the N‐methyl‐d‐aspartate receptor (NMDAR) function, may be a critical causative feature of schizophrenia, how this contributes to pathologic circuit function in the brain, and how these insights are revealing whole new avenues for treatment development that could reduce treatment‐resistant symptoms, which account for persistent disability.

show abstract

Section: The History Of Pathological Hypotheses In Schizophreniamentioning

confidence: 99%

Glutamate hypothesis in schizophrenia

Uno

Coyle

2019

Psychiatry Clin Neurosci

282

172

View full text Add to dashboard Cite

show abstract

“…Even before modern antipsychotics, ancient Greeks used an extract from the root of the Rauwolfia plant to alleviate psychosis [ 11 ]. The active ingredient was later isolated as reserpine [ 12 ].…”

Section: Molecular Pathways Underlying Schizophrenia Pathologymentioning

confidence: 99%

Dopamine, Psychosis, and Symptom Fluctuation: A Narrative Review

Novak

Seeman

2022

Healthcare

View full text Add to dashboard Cite

It has been hypothesized since the 1960s that the etiology of schizophrenia is linked to dopamine. In the intervening 60 years, sophisticated brain imaging techniques, genetic/epigenetic advances, and new experimental animal models of schizophrenia have transformed schizophrenia research. The disease is now conceptualized as a heterogeneous neurodevelopmental disorder expressed phenotypically in four symptom domains: positive, negative, cognitive, and affective. The aim of this paper is threefold: (a) to review recent research into schizophrenia etiology, (b) to review papers that elicited subjective evidence from patients as to triggers and repressors of symptoms such as auditory hallucinations or paranoid thoughts, and (c) to address the potential role of dopamine in schizophrenia in general and, in particular, in the fluctuations in schizophrenia symptoms. The review also includes new discoveries in schizophrenia research, pointing to the involvement of both striatal neurons and glia, signaling pathway convergence, and the role of stress. It also addresses potential therapeutic implications. We conclude with the hope that this paper opens up novel avenues of research and new possibilities for treatment.

show abstract